Kaleido Biosciences, Inc., a healthcare company in its clinical-stage, is positioning itself as a player in the microbiome metabolic therapies arena. The company’s development pipeline includes treatments for patients with a range of conditions, from urea cycle disorder to COVID-19. KB195 is being developed to treat urea cycle disorder; KB295 is targeting ulcerative colitis; KB174 is focusing on hepatic encephalopathy; and KB109 is being explored as a therapy to treat COVID-19. Beyond these treatments, Kaleido Biosciences is working on programs for a number of other conditions, such as immuno-oncology, and inflammatory bowel diseases. Collaboration agreements with prestigious organizations like Institute Gustave Roussy, Washington University, and Janssen underscore the promise of Kaleido’s endeavors. With its headquarters in Lexington, Massachusetts, the company was founded in 2015.